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Background: Little information is available on the mother-to-child transmission of hepatitis C
virus (HCV) in India, and no interventions to decrease transmission rates have been identified.
Hence, we performed a long-term prospective study in infants born to HCV-positive mothers, with
the aim of evaluating vertical transmission of HCV and correlated risks factors.
Methods: Three thousand one hundred and fifteen healthy asymptomatic pregnant women were
included in the study. We used third-generation (Murex anti-HCV) ELISA and HCV RNA reverse
transcriptionPCR (RT-PCR) for screening,andthecommercial lineprobeassay (Inno-LiPA)anddirect
sequencing HCV genotyping assays were performed to confirm the transmitted HCV genotypes.
Results: Of the total 3115 healthy asymptomatic pregnantwomen, 18 (0.6%)were positive for anti-
HCV. Of the 18 anti-HCV-positive women, eight (44.4%) were positive for HCV RNA RT-PCR. HCV
transmission was observed in two of the eight babies born to eight HCV RNA-positive mothers who
were followed up for 12 months. HCV genotyping of the mother/child pairs revealed the persistent
presence of mixed genotypes 1a and 4 throughout the follow-up period. None of the non-viremic
(HCVRNA-negative)mothers transmittedHCV infection to their baby. In our studyapproximately 25%
of vertical/perinatal transmission of HCVwas observed among HCV RNA-positive antenatal women.
* Corresponding author. Tel.: +91 44 22542929; fax: +91 44 22542939.
E-mail address: vvjai2000@yahoo.com (S.P. Thyagarajan).
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Conclusions: This study is of importance as it is the first report from India of a successful attempt to
analyze the rate of vertical/perinatal transmission of HCV from infected mothers to their children
by a prospective longitudinal follow-up study, and to characterize the pattern of genotype(s) of HCV
present in the infected mother/baby pairs, so as to confirm the source of HCV acquired by the
newborn babies.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Nearly 200 million people worldwide have been infected with
the hepatitis C virus (HCV). About 85% of these develop
persistent infection and are at risk of long-term complica-
tions like liver cirrhosis and hepatocellular carcinoma
(HCC).1,2 The global seroprevalence of HCV among blood
donors varies between 0.4% and 19.2%.3,4 The seroprevalence
of HCV in voluntary blood donors in India is between 0.12%
and 4%.3,5 The geographical variability of HCV seropreva-
lence can be explained by the extent to which different risk
factors contribute to the transmission of HCV infection.
Since its discovery in 1989, HCV has become the focus of
intense research for several reasons. Firstly, HCV infection
frequently becomes chronic. Secondly, there is a high burden
of infection indifferent parts of theworld.Thirdly, the absence
of a suitable vaccine and the availability of antiviral therapy
that is effective in only a small proportion of individuals have
provoked interest in themolecularbiologyof thevirus.6 In India
the overall anti-HCV positivity varies from 0.3% to 4.0%.4,5
However, vertical transmission has been shown to be facili-
tated when HCV RNA levels are high in the mother or in the
presence of concomitant HIV infection.7 In addition, genotype
analysis of HCV RNA-positive mother and child assumes sig-
nificance in the context of the necessity to establish the
genome sequence homology in the RNA-positive mother and
child to prove vertical transmission. In India there have been
very limited studies onHCVRNA statusof themother, and there
has been no long-term follow-up study to understand vertical/
perinatal transmission of HCV. Since pregnant women form a
major source of HCV transmission to their offspring if they are
infected,6,8,9 we decided to analyze the rate of vertical/
perinatal transmission of HCV infection and maternal viremic
status in a well-designed, long-term follow-up study for a
period of at least one year. We also sought to establish the
HCV genotype homology between HCV viremic mothers and
their children. This study was undertaken in healthy asympto-
matic pregnant women attending the antenatal check-up
programat government hospitals in Chennai, Tamilnadu, India.
Materials and methods
Study population and data collection
A total of 3115 asymptomatic healthy pregnant women attend-
ing the antenatal outpatient department for routine check-up
during the period June 2000 to September 2002 from various
hospitals in Chennai, Tamilnadu, Southern India were included
in the study. This studywasapprovedby the Institutional Review
Board of Dr ALM Post Graduate Institute of Basic Medical
Sciences, University of Madras, and the study design was pre-
pared and monitored by the National Institute of Epidemiology(NIE), IndianCouncil ofMedical Research (ICMR), Chennai. After
explaining thestudyandpossibleconsequencesofHCVinfection
fully, written informed consent was obtained from all mothers
prior to their registration in the study. Demographic data and
clinical details of the antenatal women were collected using a
stratified proforma developed by the NIE-ICMR.
Five-milliliterblood sampleswerecollected fromall asymp-
tomatic antenatal women; serum was separated aseptically
and stored at 70 8C until tested. After delivery the mother
and child pairs were followed if the mother was positive for
anti-HCV. Follow-up of anti-HCV-positive mothers was carried
out at 3-monthly intervals. Detailed information was collected
using the proforma at the time of antenatal check-up, at the
time of delivery, and on follow-up of the mother and child (at
the time of delivery, at 3 months, 6 months, 9 months, and 12
months). Infant serum samples were collected at birth from a
peripheral venous site, as well as during well-child visits until
the infants were 12 months old. At each visit, blood samples
were collected, information was obtained on illnesses, and a
physical examinationwas donewith the helpof anexperienced
pediatric study clinician. Blood samples were obtained from
infants at follow-up visits for the molecular level confirmation
of mother-to-infant transmission of HCV by HCV genotyping
(Inno-LiPA and HCV 50 UTR DNA sequencing).
Laboratory testing
Serum was tested for anti-HCV using two commercially avail-
able third-generation anti-HCV ELISA kits (Murex anti-HCV
version 4 and Anti-HCV by Xcyton Diagnostics, India). The RNA
was extracted from all anti-HCV-positive asymptomatic preg-
nant women using the commercially available Trizol reagent
(Life Technologies). Extracted RNA was subjected to RT
nested PCR as per the method of Panigrahi et al. (1996).5
World Health Organization (WHO) panel serum samples
obtained from the Institute for Standardization and Docu-
mentation in the Medical Laboratory (INSTAND), Dusseldorf,
Germany (WHO Collaborating Center for Quality Assurance
and Standardization in Laboratory Medicine), were used as
quality controls in all our HCV RT-PCR assays.
RNA extraction and HCV genotyping
HCV genotype was determined by using a commercially avail-
able type-specificdetection systemof thePCR-amplified50 non-
coding region (Inno-LiPA, Innogenetics, Belgium) from the
serum of all HCV RNA-positive mothers who transmitted HCV
to their babies. The Inno-LiPA was carried out according to the
manufacturer’s instructions. Briefly, viral RNA was extracted
from serum and reverse-transcribed into cDNA, followed by an
amplification step with primers complementary to the con-
served areas of the 50 untranslated region (50 UTR) of the
e396 R. Parthiban et al.different HCV types. During amplification, biotinylated primers
were incorporated into the amplified DNA fragments. Specific
oligonucleotide Inno-LiPA stripswerehybridizedwithdenatured
amplified sample material. After hybridization, streptavidin
labeled with alkaline phosphatase was added, which bound
to any biotinylated hybrid previously formed. Incubation with
nitroblue-tetrazolium/5-bromo-4-chloro-3-indolylphosphate
(NBT/BCIP) chromogen resulted in a purple/brown precipitate.
The reactivity of an amplified fragment with one or more lines
on the strip allowed the easy recognition of HCV genotypes.
The Inno-LiPA-determined transmitted HCV genotypes
were further confirmed with the direct cloning and bidirec-
tional sequencing of the independently amplified 50 UTR
amplicon. Briefly, the HCV 50 UTR amplicons were cloned
with pMOS Blue vector (pMOS cloning kit for sequencing PCR
product, Amersham Life Sciences). The cloned product was
sequenced in an ABI Prism 3700 DNA analyzer. Consensus
nucleotide sequences obtained were initially analyzed using
Gene Auto Assembler software. The mother/baby pairs
sequenced initially were then compared with the BLAST tool
program in the EMBL database (The European Molecular
Biology Laboratory). Finally the aligned sequence data were
analyzed using Clustal W multiple alignment software.
Study case definitions
Mothers were classified as HCV-positive if their serum was
found to be positive for anti-HCV by third-generation ELISA.
InfantswereclassifiedasHCV-infected if their serumwas found
tobepositive forHCVRNAonat least two follow-upvisits orwas
found to be anti-HCV-positive at the age of 12 months.
Statistical analysis
Data entry and analysis was done using SPSS version 9.5 (SPSS
Inc., Chicago, IL, USA). Descriptive statistics were used to
calculate the mean, median, and standard deviation. For all
normally distributed variables, the Student’s t-test was used
to determine the significant mean difference in various
groups. For non-normally distributed variables, the Mann—
Whitney U-test was used.
Results
Maternal characteristics
A total of 3115 healthy asymptomatic pregnant women were
screened for anti-HCV, of whom 3091 were of lower socio-
economic status and 24 were of middle and upper-middle
socio-economic status. The majority of the study subjects
(76.6%) were in the 21—30 years age group, followed by the
15—20 years age group accounting for 18.5%. The lowest anti-
HCV positivity was observed in the 31—40 years age group
(4.9% of the women, 0% positivity). Details of the socio-
demographic and risk behavior characteristics of the study
participants are shown in Table 1.
Antenatal HCV prevalence
The prevalence rate of anti-HCV among the 3115 antenatal
women screened was 0.6% (18/3115; 95% confidence interval(CI) 0.32—2.8). Forty-four percent (8/18; 95% CI 21—77) anti-
HCV-positive antenatal women were found to be positive for
HCV RNA (Table 2). All the anti-HCV-positive women were
negative for anti-HIV (HIV1 and HIV2) and hepatitis B surface
antigen (HBsAg).
Follow-up and rate of transmission
Of the 18 anti-HCV-positive women, 12 (66.7%) mother and
baby pairs were successfully followed up. Table 3 shows the
serological and molecular test results for the HCV-positive
pregnant women and their babies. Of the 12 mother and baby
pairs who were successfully followed up, nine (75%) com-
pleted 12 months of follow-up and three (25%) completed 6
months of follow-up. Six antenatal pregnant women were
lost in follow-up; in the case of one, the child died at the time
of delivery due to respiratory complications (Table 4). Of the
five cases that were lost in follow-up (not including the case
with the child that died), three mothers did not give their
consent for the follow-up and the address could not be traced
in the remaining two.
Of the total eight HCV RNA-positive mothers, four were
lost to follow-up, and transmission of the virus from the HCV
RNA-positive mother was observed in two babies. The HCV
RNA positivity continued in these children from delivery to
the 12th month (Table 3). However, both of these babies were
anti-HCV-negative from the time of delivery to the 9th month;
at 12 months one baby seroconverted and became anti-HCV-
positive. Of the twomothers who had delivered the HCV RNA-
positive babies, one had a normal vaginal delivery with a
previous history of abortion, while the other mother had a
previous history of thyroid surgery and was delivered by
cesarean.
Molecular confirmation of mother-to-child
transmission
Genotyping of the HCV RNA-positive serum samples from the
two mother/child pairs was done using a line probe assay
(Inno-LiPA HCV-II). This rapid method showed the persistent
presence of 1a and 4 mixed genotypes of HCV in all the serial
samples collected at the time of delivery and at 3 months, 6
months, 9 months, and 12 months of follow-up. The cloned
PCR products of the two mother/baby pairs were subjected
to nucleotide sequencing. Comparison of the nucleotide
sequence (280 bp) from the 50 UTR of the HCV genome
between the two mother/baby pairs showed a homology of
96% in the first mother/baby pair and 99% in the second
mother/baby pair. BLAST analysis of the genotypes 1a and 4
from the present study matched reference sequences of 1a
and 4 submitted to the EMBL database (GenBank accession
numbers DQ375758—DQ375761).
Discussion
A cross-sectional analysis of 3115 antenatal women for the
prevalence of anti-HCVantibodies showed a positivity rate of
0.6%. Numerous studies have examined the prevalence of
hepatitis C among pregnant women; these studies have
varied considerably in terms of the study sample size.10—15
In general the prevalence of detectable antibody to HCV in
Table 1 Socio-demographic and risk behavior characteristics of the study subjects







15—20 576 (18.5%) 6 (1.0%)
21—30 2385 (76.6%) 12 (0.5%)
31—40 154 (4.9%) 0 (0%)
Socio-economic status
Lower 3091 (99.2%) 18 (0.6%)
Upper middle 24 (0.8%) 0 (0%)
Educational status
Illiterate 406 (13.0%) 3 (0.7%)
Primary 242 (7.8%) 3 (1.2%)
Middle school 1105 (35.5%) 6 (0.5%)
Secondary 840 (26.9%) 4 (0.5%)
Higher secondary 330 (10.6%) 0 (0%)
Graduation 168 (5.4%) 2 (1.2%)
Post graduation 24 (0.8%) 0 (0%)
Occupational status
Housewife 2896 (93.0%) 18 (0.6%)
Agriculture 135 (4.3%) 0 (0%)
Industry 62 (2.0%) 0 (0%)
Self employed 12 (0.4%) 0 (0%)
Professional 10 (0.3%) 0 (0%)
Previous history
Jaundice 314 (10.1%) 2 (11.1%)
Hepatitis 19 (0.6%) 0 (0%)
Blood transfusion 46 (1.5%) 0 (0%)
Blood products 5 (0.2%) 1 (5.6%)
Hospitalized 1415 (45.4%) 5 (27.8%)
Other illness 0 (0%) 0 (0%)
Injection not taken in the past 2 years 533 (17.1%) 9 (50%)
Injection taken <10 times in the past 2 years 2289 (73.5%) 9 (50%)
Injection taken 10—20 times in the past 2 years 289 (9.3%) 0 (0%)
Injection taken >20 times in the past 2 years 4 (0.1%) 0 (0%)
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reviewing the available literature dealing with the epide-
miology of HCV in India, it became evident that though
analysis of certain high-risk groups and certain patient cate-
gories has been carried out, community-based studies are
lacking. In India, HCV prevalence data have mostly been
derived from blood donors, with under-representation of
women and a lack of participation of children and senior
citizens. The rate of mother-to-child HCV transmission is
critical in predicting the burden of HCV infection in future
generations.
An earlier study from India reported HCV positivity in
pregnant women to be 1.3%.20 The higher positivity in that
study could be attributed to the smaller sample size of 75
cases in contrast to the 3115 cases in the present study. TheHCV carrier state found among pregnant women varies con-
siderably as a result of differences in the number of study
subjects enrolled, geographic variables, and adequacy of
laboratory testing. The mean prevalence of anti-HCV in
studies involving more than 10 000 women is 1.26%, with
approximately 60% of anti-HCV women having detectable
HCV RNA.21—25 In our study, the HCV RNA positivity in anti-
HCV-positive women was found to be 44.4% (8/18), which is
comparable to that of the previous studies mentioned above.
No significant differences were detected between HCV RNA-
positive and RNA-negative pregnant women in terms of the
presence of clinical jaundice, serum bilirubin, alanine ami-
notransferase, aspartate aminotransferase, and serum alka-
line phosphatase. Spontaneous loss of serum HCV RNA,
interpreted as either clearance of mother-to-baby HCV
Table 2 Anti-HCV and HCV RNA positivity in the asympto-
matic pregnant women




Anti-HCV 18/3115 0.6 (0.32—2.8)
HCV RNA 8/18 44.4 (21—77)
HCV, hepatitis C virus; CI, confidence interval.
Table 4 Follow-up of anti-HCV-positive mothers and their
children (up to 12 months)
Details Number Percentage
Antenatal women anti-HCV-positive 12/18 66.7
Mother/child pairs with
12 months of follow-up
9 50.0
Mother/child pairs with
6 months of follow-up
3 16.7
Lost in follow-up 5 27.8
Death of the child 1 5.6
e398 R. Parthiban et al.infection or transient viremia, has been suggested in many
studies.9,26,27
The reported rate of mother-to-baby transmission ranges
between 0% and 35% among children born to anti-HCV-posi-
tive women.28 In our study all the babies born to anti-HCV-
positive pregnant women screened were anti-HCV-negative
at the time of delivery, and the rate of HCV RNA transmission
from mother to baby was found to be 11.1% (2/18), i.e., two
infants acquired the infection from 18 anti-HCV mothers
studied. However, the rate of HCV RNA transmission from
mother to infant is 25% if the denominator is restricted to
HCV RNAviremic women. In the present study, the two babies
had persistent viremia from birth to 12 months, with the
absence of clinical symptoms. This tendency to chronicity has
also been reported previously.29
In our follow-up, two babies were HCV RNA-positive and
anti-HCV-negative from birth until 9 months of follow-up.Table 3 Serological and molecular test results for HCV-positive
ATC, at the time of collection; 1, anti-HCV; 2, HCV RNA; NS, no sampHowever, one baby demonstrated anti-HCV seroconversion in
the 12th month. Seronegative HCV infection (absence of
serologic response to HCV polypeptides) is a well-known
entity in children born to anti-HCVand RNA-positive mothers.
Though they tend to have HCV RNA on several occasions
during their first year of life, none of the children actively
produce anti-HCV antibodies.30—32
Over the past few years, with the development of com-
mercial assays for the identification of HCV genotypes, an
impressive number of studies have investigated the molecu-
lar epidemiology of HCV infection worldwide and the effects
of HCV genotype on the pathogenesis and therapeutic out-
come of hepatitis C infection. Because of geographical clus-
tering of distinct HCV genotypes, genotyping is a useful tool
for tracing the source of an HCV outbreak in a given popula-
tion. Suspected non-conventional routes of HCV transmission
could also be investigated by molecular analysis of HCVpregnant women and their babies (n = 18)
le; +, positive; , negative.
Mother-to-child transmission of HCV, southern India e399strains from different individuals. These include the vertical
and sexual route of transmission.
Although there are considerable reports on the distinct
geographical patterns and prevalence of various hepatitis C
genotypes worldwide, including from India,33,34 studies to
evaluate the effect of HCV genotype on mother-to-baby
transmission of the virus are limited, particularly in India.
Some of the earliest studies on the transmission of HCV from
mother to baby and its genotypes, show 1b and 2a reported
from Japan35,36 and 1b and 3a reported from Italy.37,38
Another prospective study from Japan revealed that type
1b was the most prevalent, followed by 2a and 2b.
In the present study we found the presence of mixed HCV
genotypes 1a and 4, which was concordant with each
mother/baby pair. The reporting of the prevalence of geno-
type 1a is consistent with the results of previous studies on
HCV genotypes in India.20,34,39 However, the prevalence of
genotype 4 is not well established in India, though there have
been a few sporadic reports of chronically infected patients
from southern India.40 Although in our study we have
reported the prevalence of mixed genotype 1a and 4 infec-
tions in mother and baby, there have been earlier reports of
mixed genotype infections in mothers and single genotype
infections in HCV transmitted to the baby.31 In order to prove
the transmission from mother to child of the HCV genotype,
the two mother/baby pairs, analyzed at the time of delivery
and at 3 months, 6 months, 9 months, and 12 months of
follow-up with Inno-LiPA hybridization assay for genotypes,
were also subjected to direct sequencing, since nucleotide
sequencing (genomic or sub-genomic) is the gold standard for
HCV genotypes. The HCV 50 UTR sub-genomic sequence ana-
lysis in our study revealed the existence of the same geno-
types 1a and 4 in both mother/baby pairs, which had 96%
homology in the first mother/baby pair and 99% homology in
the second mother/baby pair. This confirms that the children
had acquired HCV only from their respective mothers by
vertical/perinatal means.
In conclusion, this study is of importance as it is the first
report from India of a successful attempt to analyze the rate
of vertical/perinatal transmission of HCV from infected
mothers to their children by a prospective longitudinal fol-
low-up study, and to characterize the genotype(s) of HCV
present in the HCV-infected mother/baby pairs, so as to
confirm the source of HCV acquired by the newborn babies.
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